Randomized Controlled Trial of Endovascular Therapy for Acute Large Vessel Occlusion With Large Ischemic Core
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03702413|
Recruitment Status : Recruiting
First Posted : October 11, 2018
Last Update Posted : May 29, 2019
RESCUE-Japan LIMIT(Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism Japan Large IscheMIc core Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to compare the effectiveness of endovascular treatment as compared to best medical treatment alone in the acute ischemic stroke patients with an low ASPECTS (CT-ASPECTS 3-5 or DWI-ASPECTS 3-5).
The purpose of this study is to investigate the efficacy of endovascular treatment for acute large vessel occlusion with large ischemic core (CT-ASPECT score 3-5 or DWI-ASPECT score 3-5).
|Condition or disease||Intervention/treatment||Phase|
|Mechanical Thrombectomy Large Ischemic Core||Procedure: Endovascular treatment||Not Applicable|
In the American Heart Association guideline 2018, endovascular therapy (EVT) has been strongly recommended as class of recommendation (COR) I for for the patients with acute cerebral large vessel occlusion (LVO), the Alberta Stroke Program Early CT Score (ASPECTS) 6 or more. The efficacy of EVT for the patients with low ASPECTS remains unclear.
This study is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to compare the effectiveness of endovascular treatment as compared to best medical treatment alone for acute large vessel occlusion patients with large ischemic core (ASPECTS 3-5 or DWI-ASPECTS 3-5).
Up to 200 subjects will be enrolled in the study and randomized for the Intention to treat analysis set. The randomization will be stratified by treatment institutes, patient's age (less than 75 years old or not), time from symptom onset (0-2 hours or more than 2 hours), and stroke severity (NIHSS 21 or more/less than 21), and administration of rt-PA.
Subjects who meet the inclusion criteria will be randomized in a 1:1 ratio to one of the following two treatment arms: Arm 1: best medical treatment Arm 2: best medical treatment plus endovascular treatment
Primary outcome of this study is to investigate efficacy of endivascular treatment in acute stroke patients with large ischemic core (ASPECTS 3-5 or DWI-ASPECTs 3-5) as compared to best medical treatment alone.
Approximately 40 sites in Japan Patients presenting with acute ischemic stroke (AIS) based on focal occlusion in the M1 segment of the middle cerebral artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA), determined by Magnetic Resonance Angiography (MRA) or Computed Tomographic Angiography (CTA), and who meet all eligibility criteria will be considered for study enrollment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Controlled Trial of Endovascular Therapy for Acute Large Vessel Occlusion With Large Ischemic Core (RESCUE Japan LIMIT)|
|Actual Study Start Date :||November 30, 2018|
|Estimated Primary Completion Date :||November 1, 2020|
|Estimated Study Completion Date :||June 30, 2021|
|No Intervention: Best medical treatment|
Experimental: Endovascular treatment
Best medical treatment plus endovascular treatment
Procedure: Endovascular treatment
- modified Rankin Scale ≤3 at 90 days [ Time Frame: 90 days ]
The primary endpoint of the trial is the modified Rankin Scale (mRS) ≤3 at 90 days post-stroke.The scale runs from 0-6 with 0 being perfect health without symptoms to 6 being death.
0: No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own a符airs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and a悦ention, bedridden, incontinent.
- modified Rankin Scale≤2 at 90 days [ Time Frame: 90 days ]Functional independence as difined by modified Rankin ScalemRS≤2 at 90 days
- modified Rankin Scale≤1 at 90 days [ Time Frame: 90 days ]Excellent outcome as difined by modified Rankin Scale≤1 at 90 days
- Distribution of patients across the ordinal modified Rankin scale [ Time Frame: 90 days ]The difference in linear trends in ordinal mRS outcomes between treatment groups (mRS shift analysis)
- NIHSS improvement 8 points or more at 48 hours [ Time Frame: 48 hours ]Early improvement of neulogical findings
- Symptomatic intracranial hemorrhage within 48 hours [ Time Frame: 48 hours ]Defined as NIHSS worsening of 4 or more points associated with ICH within 48 hours of randomization
- Intracranial hemorrhage within 48 hours [ Time Frame: 48 hours ]The incidence of hemorrhage
- Death [ Time Frame: 90 days ]Death due to any cause at 90 days
- Recurrence of cerebral infarction within 90 days [ Time Frame: 90 days ]Recurrence of cerebral infarction
- Propotion of subjects who required decompressive craniectomy within 7 days [ Time Frame: 7 days ]Propotion of subjects who had space-occupying infarction (malignant brain edema) and requred decompressive craniectomy within 7 days
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03702413
|Contact: Shinichi Yoshimura, PhDfirstname.lastname@example.org|